|
26 Mar 2019 |
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
|
|
26 Mar 2019 |
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
|
|
26 Mar 2019 |
Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients
|
|
25 Mar 2019 |
Alkahest Presents Positive Results from Phase 2a Open Label Study of AKST4290 in Treatment-Naïve neovascular AMD at Retina World Congress
|
|
25 Mar 2019 |
Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC™ Protein Degrader, ARV-110
|
|
25 Mar 2019 |
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
|
|
25 Mar 2019 |
PharmaMar announces positive results in its lurbinectedin monotherapy trial for small cell lung cancer
|
|
25 Mar 2019 |
Forxiga approved in Europe for type-1 diabetes
|
|
24 Mar 2019 |
Sojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical Study
|
|
24 Mar 2019 |
FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
|
|
22 Mar 2019 |
Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
|
|
21 Mar 2019 |
DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis
|
|
21 Mar 2019 |
Kaleido Biosciences Announces Initiation of Dosing in Non-IND Clinical Studies in Patients with Urea Cycle Disorders and Cirrhosis
|
|
21 Mar 2019 |
Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
|
|
21 Mar 2019 |
Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial
|
|
21 Mar 2019 |
Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis
|
|
20 Mar 2019 |
Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome
|
|
20 Mar 2019 |
Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
|
|
20 Mar 2019 |
Moleculin Announces First Patients Enrolled in Lymphoma Clinical Trial
|
|
20 Mar 2019 |
Roivant Statement on Topline Results from EMPOWUR Phase 3 Study in Overactive Bladder
|
|
20 Mar 2019 |
AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program
|
|
20 Mar 2019 |
Crinetics Pharmaceuticals Doses First Patients in Phase 2 Clinical Trials of CRN00808 for Acromegaly
|
|
20 Mar 2019 |
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
|
|
19 Mar 2019 |
NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study
|
|
19 Mar 2019 |
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
|
